Alexandria Real Estate Equities Provides Update

...ical represented approximately 13% and were dominated by high-quality, leading-edge companies with blue chip venture investors, including Ambrx, Inc., archemix Corp., Fate Therapeutics, Inc., Juvaris BioTherapeutics, Inc. and TolerRx, Inc.; and the remainder of approximately 7% was comprised of traditional ...

Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer

...icology studies for a number of biologic compounds, including monoclonal antibody immunoconjugates and nucleic acids at Millennium Pharmaceuticals and archemix Corp. Dr. Green will lead Taligen's development project teams for the company's two most advanced clinical candidates, TT30 and TA106, acros...

Isis Reports Financial Results and Highlights for Fiscal year 2007

...ction with Roche. * Isis licensed technology to archemix for aptamer drug applications in exchange for...s and royalties on aptamer drugs developed by archemix that incorporate Isis' proprietary chemistries or ...sis received the first milestone payment from archemix for the advancement of Archemix' aptamer drug into...

Archemix in Medical Technology

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...velop drugs that incorporate Isis' technology resulting in financial benefits as these assets mature. Isis earned milestone payments from archemix and Alnylam because each company advanced drugs that incorporate Isis' technology. Isis co-exclusively licensed its single-stranded RNA interfe...

Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172

...llaborative Effort In August 2006, Nuvelo expanded its collaboration with archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, archemix is responsible for discovery of short-acting aptamers for use in medical pr...

Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172

...llaborative Effort In August 2006, Nuvelo expanded its collaboration with archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, archemix is responsible for discovery of short-acting aptamers for use in medical pr...

Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172

...llaborative Effort In August 2006, Nuvelo expanded its collaboration with archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, archemix is responsible for discovery of short-acting aptamers for use in medical pr...

Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172

...llaborative Effort In August 2006, Nuvelo expanded its collaboration with archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, archemix is responsible for discovery of short-acting aptamers for use in medical pr...

Archemix Announces Completion of Phase 1 Trial of ARC1779

... CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 8, 2007 - archemix Corp., a biotechnology company focused on discover...n as thrombotic thrombocytopenic purpura, or TTP. archemix plans to present a complete data set from this Pha...esized rather than biologically expressed. About archemix ...

Archemix in Biological Technology

Biotech Avoids Fall Out From Tough Quarter for Capital Markets

...Biotech IPOs on hold The prevailing tough economic environment also took its toll on biotech IPO "hopefuls" with Biolex, Light Sciences Oncology and archemix cancelling their planned offerings because of the market conditions. Only one company braved the market -- Bioheart, a biotechnology company focused o...

Biotech Drops Amid Tough Markets in February

...otech IPOs remain on hold The prevailing tough economic environment took its toll on biotech IPO "hopefuls" with Biolex, Light Sciences Oncology and archemix cancelling their planned offerings because of the market conditions. Only one company braved the market -- Bioheart, a biotechnology company focused o...